article thumbnail

EC grants orphan drug designation for Precigen’s PRGN-2012

Pharmaceutical Technology

The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).

52
article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 The post UK biotech sees worst funding downturn since 2012 appeared first on. billion, way down from £4.5 billion in 2021. billion raised.

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market

Fierce Pharma

The traditional approvals follow initial accelerated approvals granted by the FDA in 2012 and the European Commission in 2014. It took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional nods. |

Marketing 269
article thumbnail

Texas accuses Pfizer and contract manufacturer of providing ineffective ADHD drug to state's Medicaid program

Fierce Pharma

The lawsuit further accuses the companies of manipulating quality-control testing from 2012 to 2018 to ensure samples received passing grades. . | In its lawsuit, Texas says the companies knew that deficient manufacturing processes compromised the effectiveness of Quillivant XR.

article thumbnail

A quick guide to transferring a commercial drug product to a new fill-finish CDMO  

Pharmaceutical Technology

Between 2012 and 2021, outsourcing propensity for FDA NDA injectables approvals averaged 40%, according to GlobalData’s Contract Injectable Packaging Trends…

FDA 52
article thumbnail

2023 Maddox Prize Winners Announced

Copyright Clearance Center

Since 2012, the John Maddox Prize has recognized individuals who stand up for science and advance public discussions around challenging topics.

98
article thumbnail

Precigen cuts workforce by 20% to focus on gene therapy for benign tumours

Pharmaceutical Technology

Precigen also plans to raise $30m to focus on advancing its recurrent respiratory papillomatosis (RRP) candidate PRGN-2012.

52